AGP Executive Report
Last update: 10 hours agoBiopharma Push: GC Biopharma won Ministry of Food and Drug Safety approval to start a domestic Phase 2 trial of its COVID-19 mRNA vaccine candidate, GC4006A, aiming for Phase 3 filing in 2027 and building full local mRNA-LNP production capability. Antitrust Crackdown: Seoul prosecutors summoned OCI and LG Chem executives over suspected long-running price-fixing in petrochemicals, including PVC and plasticizers, after raids in August. Energy & Trade Shock: Oil jumped above $100 as Middle East tensions and renewed missile production fears lifted prices; the Bank of Korea said it won’t rush to update its outlook despite the surge. Finance Flows Back to Banks: Major Korean banks raised one-year deposit rates into the mid-3% range, pulling cash away from markets. Small Business Relief: Korea plans to write off 5.4 trillion won in COVID-era small business loans, targeting debts under 100 million won with up to 80% principal reduction. AI Hardware Ecosystem: Korean NPU makers urged wider domestic commercial references to speed export wins, while Samsung and SK hynix momentum kept chip sentiment strong. Maritime Decarbonization: MOL named a wind-assisted LNG carrier built by Hanwha Ocean for Chevron, marking a step toward lower-fuel LNG shipping. Public Health Insight: A major review linked ADHD with significantly higher gastrointestinal problems, including constipation and IBS—an issue clinicians may overlook.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
